dm+d

Unassigned

New Medicines

Relapsed or refractory marginal zone lymphoma

Information

New molecular entity
Incyte
Incyte

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

A phosphatidylinositol 3-kinase-δ inhibitor
There are around 14,100 new non-Hodgkin lymphoma cases in the UK every year [1]. Marginal zone lymphomas (MZLs) account for between 5% and 17% of all NHL. MZLs consist of 3 different subtypes with extranodal being the most commonly reported, representing 50-70% of MZL, followed by splenic (20%) and nodal (10%) [2].
Relapsed or refractory marginal zone lymphoma
Oral